Zepbound has been studied extensively, and compounded tirzepatide has not Clinical trials for Zepbound enrolled over 5,000 participants across multiple studies, tracking weight loss, side effects, dosing schedules, and long-term outcomes over 72 weeks
23% of Americans and 16% of Britons reported no concerns about stopping GLP-1s
Research is exploring whether GLP-3 might offer cardiovascular protection through mechanisms distinct from GLP-1, complement GLP-1s cardiovascular benefits, have unique effects on heart metabolism or function, and provide benefits in cardiovascular conditions where metabolic dysfunction plays a role
[4] If you are considering adding berberine to your treatment regimen whilst taking metformin, you should always consult your GP or diabetes specialist nurse first
Semax does not produce an immediate, dramatic effect the way a stimulant does
Tirzepatide, the first in this class, improves glycemic control by increasing insulin sensitivity and lipid metabolism as well as by reducing body weight